Canaccord analyst John Young lowered the firm’s price target on Merit Medical (MMSI) to $108 from $127 and keeps a Buy rating on the shares. The firm said after a strong Q1 print, Merit’s margin expansion story just got more complicated due to tariffs. Much of the investor thesis on Merit Medical has been on margin expansion and tariffs are creating a formidable hurdle to that continued pace of expansion.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MMSI:
- Merit Medical Reports Strong Q1 2025 Results
- Merit Medical Systems Reports Q1 2025 Revenue Growth
- Merit Medical reports Q1 non-GAAP EPS 86c, consensus 75c
- Merit lowers FY25 EPS view to $3.29-$3.42 from $3.58-$3.70, consensus $3.65
- Merit Medical price target lowered to $112 from $116 at Piper Sandler